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ABSTRACT CD2 is a T cell surface glycoprotein that participates in T cell adhesion and activation. These processes are
dynamically interrelated, in that T cell activation regulates the strength of CD2-mediated T cell adhesion. The lateral redistribution
of CD2 and its ligand CD58 (LFA-3) in T cell and target membranes, respectively, has also been shown to affect cellular adhesion
strength. We have used the fluorescence photobleaching recovery technique to measure the lateral mobility of CD2 in plasma
membranes of resting and activated Jurkat T leukemia cells. CD2-mediated T cell activation caused lateral immobilization of
90% of cell surface CD2 molecules. Depleting cells of cytoplasmic Ca2 , loading cells with dibutyric cAMP, and disrupting cellular
microfilaments each partially reversed the effect of CD2-mediated activation on the lateral mobility of CD2. These intracellular
mediators apparently influence the same signal transduction pathways, because the effects of the mediators on CD2 lateral
mobility were not additive. In separate experiments, activation-associated cytoplasmic Ca2+ mobilization was found to require
microfilament integrity and to be negatively regulated by cAMP. By directly or indirectly controlling CD2 lateral diffusion and cell
surface distribution, cytoplasmic Ca2+ mobilization may have an important regulatory role in CD2 mediated T cell adhesion.
INTRODUCTION
Cellular adhesion is an important event in many biological
processes including immune cell responses (Springer, 1990).
T lymphocyte adhesion to target membranes is mediated by
several receptor-ligand pairs of cell surface molecules. CD2
and CD11a/CD18 (lymphocyte function-associated antigen
1 (LFA-1)) provide the T cell with two major adhesion path-
ways. CD2 binds CD58 (LFA-3), CD59 (Deckert et al., 1992;
Hahn et al., 1992a), and CD48 (Kato et al., 1992; Arulanan-
dam et al., 1993), whereas CD11a/CD18 binds CD54,
CD102, and CD50 (intercellular adhesion molecules 1, 2,
and 3, respectively) (Springer, 1990).
Cellular adhesion events are associated with redistribution
of adhesion molecules to sites of contact between lympho-
cyte and target membranes (Ferguson et al., 1991; Koyasu
et al., 1990). The strength of adhesion appears to be deter-
mined not only by the affinity of binding between receptors
and ligands but also by the density of these adhesion mol-
ecules at the contact sites. Redistribution of adhesion
molecules to contact sites requires that these molecules are
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able to diffuse laterally in the plasma membrane. The in-
fluence of the lateral mobility of adhesion molecules on the
strength of cellular adhesion has been demonstrated by ex-
periments in which Jurkat cells were found to adhere more
strongly to laterally mobile CD58 than to immobile CD58
reconstituted in glass-supported planar bilayer membranes
(P.-Y. Chan et al., 1991).
Activation of T cells initiates several intracellular signal-
ing pathways that lead both to nuclear activation and to
changes in the strength of T cell adhesion (Springer, 1990).
Intracellular signals appear to regulate the avidity of adhe-
sion mediated by receptor-ligand molecule pairs including
CD11a/CD18:CD54 (Dustin and Springer, 1989; Van Kooyk
et al., 1989), CD2:CD58 (Hahn et al., 1992b), CD8:MHC
class I (O'Rourke et al., 1990), and VLA integrins (CD49d/
CD29, CD49e/CD29):extracellular matrix proteins (Shimizu
et al., 1990; B. M. Chan et al., 1991). In such interactions,
intracellular signals could modulate the binding affinity
and/or the lateral mobility of the adhesion molecules. Con-
sistent with this hypothesis, correlations between cell acti-
vation and decreased membrane receptor lateral mobility
have been observed in neutrophils stimulated with fMet-Leu-
Phe (Johansson et al., 1993) and in the human T cell line
HPB-ALL stimulated with bivalent anti-CD3 monoclonal
antibody (mAb) (Hashemi et al., 1992).
Based on these observations, we hypothesized that intra-
cellular signals regulate the lateral mobility of cell surface
adhesion molecules. We examined the correlation between
T cell activation and changes in the lateral mobility of the
adhesion molecule CD2, and the mechanisms by which in-
tracellular signals regulate CD2 mobility. In addition to its
receptor function in cellular adhesion, the CD2 molecule it-
self can be stimulated to induce T cell activation. T cell
proliferation and IL-2 production are triggered not only via
the T cell receptor for antigen (TCR) but also upon binding
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of two CD2-specific signals including CD58 and an anti-
CD2 mAb or pairs of anti-CD2 mAbs (Meuer et al., 1984;
Brottier et al., 1985; Bernard et al., 1986; Bierer et al.,
1988b). Also, T cell proliferation and IL-2 production are
enhanced upon co-stimulation of the TCR and CD2 (Hahn
et al., 1992a). Using the CD2+ T leukemia cell line Jurkat,
we examined first the effect ofT cell activation on the lateral
mobility of CD2. Activating pairs of anti-CD2 mAbs mark-
edly decreased the laterally mobile fraction of CD2 mol-
ecules. We then used this activation-associated CD2 immo-
bilization as a model system to study the roles of cytoplasmic
mediators, including cytoplasmic free calcium ions ([Ca21]i)
and cAMP, and of microfilaments in modulating CD2 lateral
diffusion.
MATERIALS AND METHODS
Cell culture
Jurkat T leukemia cells were maintained in RPMI 1640 (Sigma Chemical
Co., St. Louis, MO) supplemented with 10% heat-inactivated FBS (Hyclone
Laboratories, Inc., Logan, UT), 100 units/ml penicillin-100 ,ug/ml strep-
tomycin (Sigma), 3 mM glutamine (Gibco BRL, Gaithersburg, MD) and 50
,uM 2-mercaptoethanol (Sigma) at 37°C in a 5% CO2 atmosphere.
mAbs
Murine anti-CD2 mAbs included TS2/18 (IgGl) (Sanchez-Madrid et al.,
1982) and 9.6 (IgG2a) (Kamoun et al., 1981), and the murine anti-CD2R
mAb was 9-1 (IgG3) (Bernard et al., 1986). mAbs 9.6 and 9-1 were the
generous gifts of Drs. Paul Martin and Patrick Trown, respectively. TS2/18
and 9-1 were used as purified IgG; 9.6 was used as ascites fluid. Fab frag-
ments of TS2/18 were prepared by papain treatment (Harlow, 1988). Im-
mobilized papain (Calbiochem, San Diego, CA; 2 mg papain/ml gel) was
activated by incubation in 100 mM cysteine, 100 mM Na acetate, 3 mM
EDTA, pH 5.5 at 370C for 30 min. Activated papain was washed 3 times
with 100mM Na acetate, 3 mM EDTA, pH 5.5. TS2/18 was incubated with
activated papain beads at 37°C for 6 h and then dialyzed overnight against
PBS, pH 7.5. Fc fragments and remaining intact antibody molecules were
removed by incubation with affigel protein A (Bio-Rad Laboratories, Rich-
mond, CA) at 40C for 45 min. SDS-PAGE analysis of the fraction containing
Fab fragments showed a single protein band at molecular weight 50,000
under nonreducing conditions. TS2/18 was conjugated to fluorescein iso-
thiocyanate (FITC), as described (Golding, 1976; Stolpen et al., 1988). The
protein concentration was determined by measuring the optical density at
280 nm. The FITC:mAb molar ratio was about 1, as determined by mea-
suring the optical density at 493 and 280 nm (Stolpen et al., 1988). mAbs
were centrifuged at 100,000 X g (Airfuge; Beckman Instruments, Inc., Palo
Alto, CA) for 30 min or 16,000 X g (Eppendorf microcentrifuge; Brinkmann
Instruments, Inc., Westbury, NY) for 1 h. Both conditions of centrifugation
yielded equivalent experimental results (data not shown).
Treatment and labeling of cells with mAbs
Cells were washed with HEPES-buffered saline (HBS; 140mM NaCl,2mM
KCI, 0.5 mM CaCl2, 0.5 mM MgCl2, 20 mM HEPES, 5.6 mM glucose, pH
7.4), incubated at 5 x 106 cells/ml with mAbs (50 ,ug/ml) on ice in the dark
for 30 min, and washed with HBS.
Treatment of cells with mediators and
cytoskeletal inhibitors
Cytochalasin D (Sigma) and ionomycin (Sigma) were dissolved in ethanol
to make stock solutions of 1 mM and 250 ,M, respectively. Other reagents
were dissolved in HBS. All reagents were present in the cell suspension
throughout the experiment.
Depletion of intracellular Ca2l
Cells (5 X 106/ml) were incubated at room temperature with 10 mM EGTA
(Sigma) and 10 AM ionomycin for 1 h. EGTA was used to chelate extra-
cellular Ca2" and ionomycin to increase plasma membrane Ca21 perme-
ability. Ca2' efflux, driven by the outward [Ca21] gradient across the mem-
brane, thereby depleted intracellular Ca2+. As a control, the extracellular
medium alone was depleted of Ca2' by incubation of cells with 10 mM
EGTA for 2-5 min.
Loading of cells with dibutyric cAMP
Cells (5 X 106/ml) were treated at room temperature with 2 mM dibutyric
cAMP (Db cAMP) (Sigma) or 2 mM butyrate (Sigma) for 15 min. Butyrate
was used as a control for the effects of the most abundant degradation
product of Db cAMP.
Inhibition of cytoskeletal function
Cells (about 106/ml) were treated at 37°C for 2 h 20 min with 20 ,uM
cytochalasin or 20 ,uM colchicine, or for 2 h 20 min or 4 h with
20 AM cytochalasin and 20 ,uM colchicine.
Conditions
Sequential treatment(s) of cells employed the same conditions as those used
for individual treatments (see Table 2).
After treatments Jurkat cells were incubated on ice in the dark for 30 min
with either FITC-TS2/18, the mAb combination FITC-TS2/18 + 9-1, the
combination TS2/18 + FITC-9-1, or the combination TS2/18 + 9-1. Each
mAb was added at a concentration of 50 ,ug/ml.
None of the treatments induced changes in cell morphology by phase
contrast microscopy. Ethanol controls did not affect the lateral mobility of
CD2 labeled with TS2/18 + 9-1 (data not shown).
Fluorescence photobleaching recovery
FPR experiments (Axelrod et al., 1976) were performed at room temperature
using an ACAS 570 interactive laser cytometer (Meridian Instruments, Inc.,
Okemos, MI). The Gaussian beam radius was 1 ,um, and excitation and
emission wavelengths were 488 and 510 ± 5 nm, respectively. Photobleach-
ing power at the sample was about 0.5 mW, and the bleaching time was
40-50 ms. The photobleaching beam was positioned in central areas of cells,
away from the peripheral ring staining of the plasma membrane. The frac-
tional mobility (ft, i.e., the fraction of FITC-labeled protein that was free to
diffuse in the plane of the membrane), and the diffusion coefficient (D) of
the mobile fraction were obtained by using nonlinear least-squares analysis
of fluorescence recovery curves (Golan et al., 1986) (see Fig. 1).
Cytoplasmic free calcium ion
concentration ([Ca2+J1).
Fluo-3 (Molecular Probes, Eugene, OR) was dissolved at 1 mM in dim-
ethylformamide (Fisher, Pittsburgh, PA). Fluo-3 solution was mixed with
Pluronic F-127 (Molecular Probes) dissolved in dimethylformamide at 2 g
of Pluronic F-127 per mole of fluo-3. Cells (5 X 106/ml) were incubated at
room temperature for 1 h with 10,M fluo-3 in HBS and then washed 3 times
with HBS. The ACAS 570 interactive laser cytometer was used to image
individual fluo-3-loaded cells using an excitation wavelength of 488 nm and
an emission wavelength of 510 + 5 nm, and the integrated single cell fluo-
rescence intensity was measured at room temperature. Calibration of fluo-3
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fluorescence and calculation of [Ca2+]i were based on the method described
by Kao et al. (1989). The fluorescence intensity of intracellular fluo-3 satu-
rated with Mn2+ was obtained by incubating fluo-3-loaded cells at room
temperature with 10 ,uM ionomycin for 5 min and then with 2 mM MnCl2
for 15 min. One percent Triton X-100 (Bio-Rad Laboratories) was added
to fluo-3-loaded cells to obtain the background fluorescence. Control single
cell fluorescence intensity was measured immediately after fluo-3 loading.
The mAb pair TS2/18 + 9-1 (each at a concentration of 50 ,ug/ml) was then
added to the cell suspension, and single cell images were taken. All mea-
surements were taken between 2 and 60 min after mAb addition, and results
were analyzed as a function of time (see Results). A different cell was
imaged for each data point. The fluorescence intensity of control cells did
not vary over the time course of the experiments (data not shown). Ra rep-
resents the fraction of cells with [Ca2+]i greater than 332 nM, which was the
mean (116.8 nM) + 2 X SD (107.6 nM) intracellular [Ca2+] for resting
control cells (n = 92). P, the percentage of Jurkat cells with elevated [Ca2+]i
in the absence of TS2/18 + 9-1 treatment, was used to estimate the number
of high [Ca2+]i cells in the background. This background was subtracted
from T, the total number of cells measured, and from H, the number of cells
with elevated [Ca2+]i after addition of TS2/18 + 9-1. That is, Ra = (H -
T X P)I(T - T X P). P was calculated independently for each experiment;
its magnitude was 3-42% for control cells, 14-35% for Db cAMP-treated
cells, 0% for EGTA + ionomycin-treated cells, and less than 20% for
cytochalasin-, colchicine-, EGTA-, and butyrate-treated cells.
RESULTS
Activation of Jurkat T cells is associated with
lateral immobilization of cell surface CD2
We used CD2+ Jurkat T leukemia cells to investigate the
regulation of CD2 lateral mobility by T cell activation. Cells
were stimulated with pairs of anti-CD2 mAbs, including
TS2/18 + 9-1, which induced a significant increase in [Ca2+]i
(see below), and 9.6 + 9-1, which stimulates not only in-
creased [Ca2+]i but also T cell proliferation and IL-2 pro-
duction (Bernard et al., 1986; Yang et al., 1986; Hahn et al.,
1991). The anti-CD2 mAbs TS2/18, 9.6, and 9-1 (an anti-
CD2R mAb) bind to different epitopes of CD2 (Peterson and
Seed, 1987; Bierer et al., 1988a). The epitopes to which
TS2/18 and 9.6 bind are highly expressed on resting T cells,
whereas the 9-1 epitope (CD2R) is weakly present on resting
cells and highly expressed on activated cells (Yang et al.,
1987). Binding of TS2/18 (see below) or 9.6 (Yang et al.,
1986, 1987) to CD2 enhances the expression of the CD2
epitope to which 9-1 binds on T cells. In contrast to treatment
with stimulating pairs of anti-CD2 mAbs, treatment with the
single mAb TS2/18 or with the Ab pair TS2/18 + goat anti-
mouse IgG2a (an irrelevant antibody) did not induce an in-
crease in [Ca2+]i (data not shown). This finding is consistent
with the observation that single anti-CD2 mAbs are unable
to stimulate T cells to proliferate or to induce [Ca2+]i eleva-
tion (Wallace et al., 1987). We therefore used TS2/18-
labeled cells as controls for cells treated with stimulating
pairs of anti-CD2 mAbs.
The fractional mobility (J) of FITC-TS2/18-labeled CD2
in plasma membranes of resting cells was 70%, and the lat-
eral diffusion coefficient (D) was 7.2 X 10-10 cm2 s-1
(Fig.1, A and B; Table 1). These f and D values are typical
for many transmembrane proteins in biological membranes.
Addition of the anti-CD2R mAb 9-1 to FITC-TS2/18-labeled
cells caused the fractional mobility of CD2 to decrease to
37% after 10 min of incubation and to less than 10% after
60 min of incubation (Fig. 1, C and D; Fig. 2 A).' Similar
reductions in CD2 mobility were observed in cells treated
with the mAb pairs TS2/18 + FITC-9-1 and 9.6 + FITC-9-1
(Table 1), but were not observed in cells treated with the mAb
pair TS2/18 + goat anti-mouse IgG2a. Cells treated with the
single mAb FITC-9-1 did not exhibit sufficient fluorescence
signal to allow performance of a valid FPR experiment (see
above). Thus, the fraction of laterally mobile CD2 molecules
decreased significantly upon stimulation of Jurkat T cells
with activating pairs of anti-CD2 mAbs.
Because an apparent decrease in fractional mobility could
result from internalization of a labeled cell surface receptor
(Thatte et al., 1994), we investigated the possibility that pairs
ofanti-CD2 mAbs induce CD2 internalization and, therefore,
apparent CD2 immobilization. Internalization of fluores-
cently labeled CD2 would be expected to shift the fluores-
cence intensity distribution from the periphery ("rim stain")
to the center of cells. The distribution of fluorescence in-
tensity along the axis of laser scanning was similar for resting
cells and for cells stimulated with pairs of anti-CD2 mAbs,
however (Fig. 1, A and C). The fluorescence intensity at the
perimeter of FITC-TS2/18-labeled cells was 2.5-3-fold
greater than that in the center of cells (Fig. 1 A), and anti-CD2
mAb pairs did not significantly alter this distribution of cell
surface fluorescence intensity for at least 60 min after mAb
treatment (Fig. 1 C). In addition, the fluorescence intensity
in the center ofFITC-TS2/18-labeled cells remained constant
for at least 90 min after addition of 9-1 (Fig. 2 D and data
not shown). These results suggest that internalization of fluo-
rescence was not induced by pairs of anti-CD2 mAbs (Thatte
et al., 1994), and that CD2 internalization was not respon-
sible for the marked decrease in CD2 mobility. Rather, these
results show that >90% ofCD2 molecules were immobilized
at the cell surface upon activation of T cells by pairs of
anti-CD2 mAbs.
Extensive cross-linking of cell surface receptors by pairs
of mAbs directed against different epitopes on the receptors
could result in lateral immobilization. To investigate this
possibility, we attempted to label CD2 with a nonactivating
pair of anti-CD2 mAbs, FITC-TS2/18 + 9.6. We found,
however, that 9.6 markedly decreased the fluorescence in-
tensity of FITC-TS2/18 on the cell surface, causing the signal
to be too weak for performance of a valid FPR experi-
ment.2 As a second control, cells were simultaneously
treated with FITC-9-1 and Fab fragments of TS2/18. This
mAb combination, which is not capable of extensively
cross-linking cell surface CD2 molecules, nonetheless
induced both a significant increase in [Ca21]i (Ra = 0.43;
1 After the 60 min incubation period, >90% of both control and activated
cells remained viable as measured by trypan blue exclusion.
2Although TS2/18 and 9.6 have been found to bind to different epitopes of
CD2 (Bierer et al., 1988a), steric hindrance interactions between TS2/18 and
9.6 may prevent simultaneous binding of these two anti-CD2 mAbs.
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FIGURE 1 Representative fluorescence photobleaching recovery (FPR) measurements of CD2 lateral mobility in resting Jurkat T cells labeled
with FITC-TS2/18 (A, B) and in activated cells labeled with the mAb combination FITC-TS2/18 + 9-1 (C, D). A and C show the linear profiles
of fluorescence intensity before the photobleach (a), immediately after the photobleach (b), and 60 s after the photobleach (c) obtained by using
the Meridian ACAS 570 interactive laser cytometer in line scan mode. The location of the photobleach is marked by a vertical line. The corresponding
FPR curves are presented in B and D. Crosses represent experimental data points. ,u is the fraction by which the fluorescence intensity is decreased
after the photobleach at time = 0. Data points are fitted by nonlinear least-squares analysis. (A, B) D = 6.1 X 10-10 cm2 s-1; f = 94%. (C, D)
f = 0%; D cannot be measured.
see legend to Fig. 3) and lateral immobilization of CD2
(Table 1). T cell activation, rather than cross-linking of
CD2 molecules at the cell surface, therefore appeared to
be responsible for the lateral immobilization of CD2 in-
duced by pairs of anti-CD2 mAbs.
Cross-linking of CD2 by pairs of anti-CD2 mAbs could
also cause clustering ofCD2 into patches in the plasma mem-
brane. Fluorescence imaging of single cells labeled with
FITC-TS2/18 or FITC-TS2/18 + 9-1 showed peripheral ring
staining of the plasma membrane for at least 60 min after
mAb labeling. Twenty-nine percent of FITC-TS2/18-labeled
(control) cells (n = 37) and 46% of FITC-TS2/18 + 9-1-
treated (activated) cells (n = 37) were found to have 1-2
small ('2 ptm diameter) fluorescent patches in the mem-
brane. Therefore, the presence of CD2 patches did not de-
pend on treatment with stimulating pairs of anti-CD2 mAbs,
although cell activation through CD2 modestly increased
CD2 patching. The modest difference between the fractions
of activated and control cells with FITC-TS2/18-labeled
patches could not account for the profound decrease in CD2
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TABLE 1 Pairs of anti-CD2 mAbs cause lateral
immobilization of CD2 in Jurkat T cells
lst mAb 2nd mAb D f N
FITC-TS2/18 7.2 ± 0.2* 70 ± 1 (1, 2, 3, 4) 262
TS2/18 FITC-9-1 ND <10 (1) 47
FITC-TS2/18 9-1 ND <10 (2) 102
9.6 FITC-9-1 ND <10 (3) 48
TS2/18(Fab) FITC-9-1 ND 13 ± 2(4) 49
D, diffusion coefficient, X 1010 cm2 s- ;f, fractional mobility, %; N, number
of measurements; ND, D cannot be determined forf < 20%.
*Mean ± SEM.
1, 2, 3, 4: p < 0.001, Student two-tailed t-test.
lateral mobility, however. These results support the conclu-
sion that excessive cross-linking of CD2 was not responsible
for CD2 immobilization induced by pairs of anti-CD2 mAbs.
Roles of intracellular mediators in
activation-associated CD2 immobilization
Intracellular signals induced by cell activation appear to
regulate the avidity of adhesion molecules such as CD2
(Hahn et al., 1992b). We therefore examined whether
activation-associated CD2 immobilization is mediated by in-
tracellular signals. Because the stimulating mAb pair TS2/18
+ 9-1 caused a significant increase in [Ca2+]i (Fig. 2)
whereas the single mAb TS2/18 did not elevate [Ca2]1i (data
not shown), we first investigated the role of cytoplasmic Ca2+
mobilization in CD2 immobilization.
Pretreatment of cells with EGTA and ionomycin was
found to reduce [Ca2+]i in resting cells and to prevent the
[Ca2+]i increase induced by treatment with TS2/18 + 9-1
(Fig. 3). Cells depleted of intracellular Ca2+ also manifested
fewer patches of CD2 in the plasma membrane (14% of
FITC-TS2/18-labeled (control) cells (n = 50) and 38% of
FITC-TS2/18 + 9-1-treated (activated) cells (n = 50)).
Depletion of [Ca2+]i by EGTA + ionomycin partially re-
versed the lateral immobilization of CD2 induced by TS2/18
+ 9-1, without significant effect on the mobility of CD2 in
resting, FITC-TS2/18-labeled cells (Table 2). The latter ob-
servation, together with the finding that EGTA alone did not
alter the mobility of CD2 labeled with FITC-TS2/18 (Table
2), renders unlikely the possibility that perturbation of mem-
brane structure by ionomycin affected CD2 mobility directly.
Depletion of extracellular Ca2' by EGTA had little effect on
Figure 2
f (%)
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A f (%)
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Time (min)
FIGURE 2 Kinetics of CD2 fractional mobility (A, B), intracellular [Ca21] (C), and membrane fluorescein fluorescence intensity (D) in Jurkat T cells
stimulated by the mAb combination FITC-TS2/18 + 9-1. (A) Cells were labeled with FITC-TS2/18 (50 p,g/ml). mAb 9-1 (50 jig/ml) was then added to
the cell suspension immediately before FPR measurements (0). In some experiments cells were pretreated with 10 mM EGTA and 10 JIM ionomycin at
room temperature for 1 h, labeled with FITC-TS2/18, and then treated with 9-1 (@). Data points represent mean ± SEM of 10-20 measurements from 6
independent experiments in each time interval. By the Student two-tailed t-test, p > 0.1 for f values with and without EGTA + ionomycin pretreatment
between 0 and 10 min, and p < 0.02 forf values between 11 and 60 min after the addition of 9-1. (B) Difference, Af, between the fractional mobility of
CD2 with and without EGTA + ionomycin pretreatment. Primary data are shown in A. (C) Cells were loaded with fluo-3. TS2/18 (50 ,ug/ml) and 9-1
(50 ,g/ml) were added to the cell suspension immediately before measurements of integrated cellular fluorescence intensity, which commenced at time = 0. Ra is
the fraction of cells with [Ca2+]i significantly greater than that of resting control cells, calculated as described in Materials and Methods. Data points represent
mean ± SEM of 5 independent experiments, each of which involved [Ca2]i measurements on 15-47 cells in each time interval. (D) Cells were labeled
with FITC-TS2/18 (50 gg/ml) and then with 9-1 (50 ,ug/ml). The fluorescence intensity in the center of each cell was measured as a function of time after
the addition of 9-1, which occurred at time = 0. The fluorescence intensity (Fl) was then normalized by the average fluorescence intensity (Av Fl) for each
individual experiment. Data points represent mean ± SEM of 15-19 measurements from 6 independent experiments in each time interval.
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FIGURE 3 Effects of cellular pretreatments on [Ca2]i in resting Jurkat
T cells (A) and on the elevation in [Ca2]j stimulated by treatment with
TS2/18 + 9-1 (B). Intracellular Ca21 concentration was calculated as de-
scribed in Materials and Methods. EGTA + ionomycin, cytochalasin, and
colchicine pretreatments were carried out before fluo-3 loading, and EGTA,
Db cAMP, and butyrate pretreatments were performed after fluo-3 loading.
(A) Data points represent mean ± SEM of measurements on 92 control, 50
EGTA + ionomycin-, 65 EGTA-, 62 cytochalasin-, 37 colchicine-, 51 Db
cAMP-, and 60 butyrate-pretreated cells. By the Student two-tailed t-test,
compared with the [Ca2+]i value of control cells, p > 0.2 for the [Ca2+]
values of EGTA-, cytochalasin-, colchicine-, and butyrate-pretreated cells,
p = 0.1 for the [Ca2+]i value of Db cAMP-pretreated cells, and p < 0.001
for the [Ca21]i value of EGTA + ionomycin-pretreated cells. (B) TS2/18
(50 ,ug/ml) and 9-1 (50 ,ug/ml) were added to fluo-3-loaded cells imme-
diately before measurements of cellular fluorescence. Ra was calculated as
described in Materials and Methods. Ra was determined over a period of 60
min after addition of TS2/18 + 9-1. The background, which was measured
after each pretreatment, was subtracted from the experimental Ra value. Data
points represent mean ± SEM of five independent experiments for control
cells, three independent experiments for EGTA-, cytochalasin-, Db cAMP-,
and butyrate-pretreated cells, and two independent experiments for EGTA
+ ionomycin- and colchicine-pretreated cells. By the Student two-tailed
t-test, compared with the Ra value for control cells, p < 0.01 for the Ra value
of EGTA + ionomycin, cytochalasin and Db cAMP pretreated cells, p <
0.05 for the Ra value of colchicine treated cells, and p > 0.2 for the Ra value
ofEGTA- and butyrate-pretreated cells. Data from all experiments were also
pooled, and the aggregate Ra values were calculated for each pretreatment.
The probabilistic independence of each pretreatment was tested by contin-
gency table analysis (StatView 512+, Brain Power, Inc., Calabasas, CA).
p values compared to control were <0.0001 for EGTA + ionomycin, cyto-
chalasin, and Db cAMP pretreatments, and >0.2 for EGTA, colchicine, and
butyrate treatments. The total numbers of cells examined were 444 for con-
trol, 204 for EGTA + ionomycin, 315 for EGTA, 250 for cytochalasin, 185
for colchicine, 284 for Db cAMP, and 331 for butyrate pretreatments. Ra for
cells activated with TS2/18(Fab) + 9-1 was 0.43, and the total number of
cells examined was 77.
[Ca2"]i in resting cells or on the [Ca2"]i increase stimulated
by pairs of anti-CD2 mAbs (Fig. 3). In contrast to the effect
of EGTA + ionomycin, EGTA alone only minimally re-
versed the CD2 immobilization induced by TS2/18 + 9-1
(Table 2). These data suggest that low extracellular [Ca2t]
was not primarily responsible for the reversal of CD2 im-
mobilization by treatment with EGTA + ionomycin. Instead,
the data imply that EGTA + ionomycin reversed activation-
associated CD2 immobilization by affecting cytoplasmic
Ca2+ mobilization in stimulated cells. It is also possible that
treatment with EGTA + ionomycin perturbed the signal
transduction machinery of the cell independent of an effect
on intracellular [Ca2+]. These results are consistent with our
recent observation that cytoplasmic Ca2+ mobilization,
stimulated by cross-linking of the TCR/CD3 complex,
causes partial immobilization of CD2 in Jurkat T cell mem-
branes (Liu and Golan, 1994a).
To examine further the relationship between increased
[Ca2t]i and CD2 immobilization, we compared the kinetics
of mAb-induced changes in [Ca2+]i and CD2 lateral mobility
in control cells and in cells pretreated with EGTA + iono-
mycin (Fig. 2). In control cells [Ca2+]i increased immediately
upon stimulation with TS2/18 + 9-1, whereas CD2 lateral
mobility decreased 10 min after stimulation. Therefore, in-
tracellular Ca2+ mobilization cannot be a consequence of
CD2 immobilization but it could serve to trigger CD2 im-
mobilization. Both the difference (Af) between the fractional
mobility of CD2 with and without EGTA + ionomycin pre-
treatment and the level of increase in [Ca21]i in control cells
increased over the first 20 min after mAb treatment (Fig. 2,
B and C), suggesting that release of Ca2+ from intracellular
stores is important for CD2 immobilization. [Ca2]i was
found to decline about 35 min after mAb treatment, whereas
Afremained constant at a level of about 20% (Fig. 2, B and
C). Together with the observed 10 min delay between the
initial increase in [Ca2t]i and the initial decrease in CD2
mobility, these data suggest that the modulation of CD2 mo-
bility by [Ca2+]i is mediated by intermediate molecular
events. Consistent with this hypothesis, our recent finding
that calmodulin inhibition partially reverses the CD2 immo-
bilization induced by pairs of anti-CD2 mAbs (Liu and
Golan, 1994b) suggests that calmodulin serves as one me-
diator of Ca2+-associated CD2 immobilization. We at-
tempted to increase cytoplasmic [Ca2+] by treatment with
ionomycin and 1 mM extracellular Ca2+, and thereby to
measure directly the effect of increased [Ca2+]i on CD2 lat-
eral mobility. We found, however, that both cytoplasmic
Ca21 concentrations and CD2 fractional mobilities varied
significantly among cells after ionomycin + Ca2+ treatment.
For example, f values ranged from <10 to 70%, with an av-
erage value of 27 ± 6% (n = 19). Also, sustained high
[Ca2+]i typically resulted in cell death.
cAMP up-regulates the binding of CD2+ cell lines to pu-
rified CD58 (Hahn et al., 1993), and binding of CD58 or
TS2/18 to CD2 transiently increases cAMP levels in both T
cell lines and resting purified T cells (Hahn et al., 1991). To
examine the effect of cAMP levels on CD2 mobility, we
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TABLE 2 Intracellular Ca2+, cAMP, and microfilaments regulate CD2 lateral mobility in membranes of activated Jurkat T cells
mAb Labeling
FITC-TS2/18 TS2/18+9-1*
Treatment D f N D f N
None 7.2 ± 0.2t 70 ± 1 262 ND <10 (1, 2, 3) 149
a) EGTA+Ionomycin 8.8 ± 0.5 67 ± 2 77 7.5 ± 0.6 35 ± 3 (1,4) 52
b) EGTA 7.5 ± 0.4 73 ± 2 65 ND 16 ± 2 (4) 80
c) Db cAMP 7.8 ± 0.4 59 ± 2 140 7.2 ± 0.7 29 ± 3 (2) 63
d) Butyrate 6.0 ± 0.5 50 ± 4 37 ND 11 ± 3 17
e) Cytochalasin 7.9 ± 0.6 68 ± 2 41 7.8 ± 0.7 30 ± 2 (3) 49
f) Colchicine 6.5 ± 0.7 71 ± 3 25 ND <10 45
g) e+f, 2 hr 20 min 8.4 ± 0.8 73 ± 5 10 8.8 ± 1.3 25 ± 4 21
h) e+f, 4 hr 9.8 ± 2.2 25 ± 3 10
a c 7.7±1.2 62±5 21 7.2± 1.6 38±4 26
a e 8.9 ± 0.7 75 ± 3 38 6.2 0.7 40 ± 3 36
c e 6.7 ± 0.3 74 ± 2 44 7.9 0.9 31 ± 2 65
a c--),. e 9.9 ± 1.9 71 ± 6 17 7.0 1.2 41 ± 4 20
D, diffusion coefficient, X 1010 cm2 s- ; f, fractional mobility, %; N, number of measurements; ND, D cannot be determined for f < 20%.
*Pairs of mAbs, including both FITC-TS2/18 + 9-1 and TS2/18 + FITC-9-1.
tMean ± SEM.
1,2,3,4: p < 0.001; Student two-tailed t-test.
loaded cells with the cAMP analog dibutyric cAMP (Db
cAMP). Like EGTA + ionomycin pretreatment, Db cAMP
loading partially reversed the immobilization of CD2 in-
duced by TS2/18 + 9-1. In contrast, the functionally inactive
metabolite of Db cAMP, butyrate, had no effect on mAb-
induced CD2 immobilization (Table 2). The slight reduction
in CD2 fractional mobility in resting cells treated with Db
cAMP could be due to the effect of butyrate released as a
breakdown product of intracellular Db cAMP, because bu-
tyrate alone reduced thefvalue ofCD2 in resting cells (Table
2). Because pretreatment with Db cAMP increased CD2 frac-
tional mobility in cells stimulated with pairs of anti-CD2
mAbs but not in resting cells, cAMP appears to interrupt the
signal transduction pathway by which T cell activation leads
to CD2 immobilization.
CD2 is the receptor on T cells that mediates rosetting of
sheep erythrocytes (Van Wauwe et al., 1981; Kamoun et al.,
1981; Howard et al., 1981). Erythrocyte rosette formation is
prevented by pretreating T cells with the microfilament dis-
rupting agent cytochalasin but not with the microtubule in-
hibitor colchicine (Freed et al., 1989; Ishijima et al., 1991).
Further, CD2 appears to associate with a/,B tubulin, an as-
sociation that is decreased by CD2-mediated T cell activation
(Offringa and Bierer, 1993). We therefore examined the roles
of cytoskeletal proteins in regulating CD2 mobility by treat-
ing cells with cytochalasin or colchicine. These treatments
did not affect the ability of fluorescent anti-CD2 mAbs to
label CD2. Pretreatment of cells with cytochalasin caused the
fractional mobility of CD2 in cells stimulated with FITC-
TS2/18 + 9-1 to increase significantly, but had no effect on
the mobility of CD2 in TS2/18-labeled resting cells (Table
2). These data suggest that microfilaments are involved in the
regulation of CD2 mobility in activated cells but not in un-
stimulated cells. CD2 immobilization by TS2/18 + 9-1 could
be at least partially mediated either by modulation of direct
interactions between CD2 and the microfilament-based cyto-
skeleton or by an indirect microfilament-mediated signal
transduction process. Pretreatment of cells with colchicine
did not alter either the immobilization of CD2 by TS2/18 +
9-1 or the lateral mobility of CD2 in resting cells (Table 2).
Therefore, microtubules do not appear to regulate CD2 mo-
bility in either activated or unstimulated cells.
Having shown that perturbations of [Ca21]i, cAMP levels
and microfilament integrity individually modulate CD2
mobility, we investigated whether these intracellular media-
tors act through independent pathways. Combinations of
these pretreatments followed by incubation with TS2/18 +
9-1 yielded CD2 fractional mobilities of 33-41% (Table 2),
showing no additive effects. [Ca2+]i, cAMP, and microfila-
ment integrity therefore appear to be involved in the same
signal transduction pathway leading to mAb-induced CD2
immobilization.
Effects of intracellular mediators on
activation-associated Ca2+ mobilization
Because increased [Ca2+]i correlated directly with CD2 im-
mobilization (Fig. 2, Table 1), we attempted to dissect the
signal transduction pathways leading to CD2 immobilization
by examining the effects of intracellular mediators on the
increase in [Ca2+]i induced by TS2/18 + 9-1 treatment
(Fig.3). As expected, pretreatment of resting cells with
EGTA + ionomycin significantly reduced [Ca2+]i and abol-
ished the [Ca2+]i rise stimulated by TS2/18 + 9-1. Mobili-
zation of cytoplasmic Ca2+ was predominantly responsible
for the mAb-induced increase in [Ca2+]j, because pretreat-
ment of cells with EGTA alone did not significantly reduce
the [Ca2+]i rise (Fig. 3). Cytochalasin pretreatment inhibited
cytoplasmic Ca2+ mobilization, whereas colchicine pretreat-
ment had no effect. Because treatment with cytochalasin did
not alter [Ca2+]i in resting cells, it is unlikely that cytochal-
asin regulates [Ca2+]i directly. Rather, cytochalasin appears
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to inhibit mAb-induced Ca2" mobilization by disruption of
cellular microfilaments. CD2-mediated T cell activation may
therefore require microfilament integrity. Cells pretreated
with Db cAMP, like those pretreated with cytochalasin, did
not manifest an increase in [Ca21]i in response to TS2/18 +
9-1 treatment (Fig. 3). Pretreatment with butyrate, in con-
trast, did not inhibit Ca2+ mobilization upon mAb-induced
cell activation. The specific effect of Db cAMP in our system
is consistent with the observations that cAMP blocks the
[Ca2+]i increase induced by the anti-CD3 mAb OKT3
(Papadogiannakis et al., 1989) and reduces diacylglycerol
and inositol phosphate generation stimulated by pairs of anti-
CD2 mAbs (Bismuth et al., 1988).
DISCUSSION
We have shown that pairs of anti-CD2 mAbs markedly re-
duce CD2 lateral mobility in Jurkat T leukemia cells, and that
this effect correlates with the induction of elevated [Ca2+]i.
EGTA and ionomycin, Db cAMP, and cytochalasin treat-
ments individually inhibit both the increase in [Ca2+]i and the
immobilization of CD2. Also, each of these treatments ap-
pears to act on a common pathway leading to CD2 immo-
bilization. The ability of EGTA and ionomycin, Db cAMP,
and cytochalasin to affect CD2 mobility appears to be me-
diated, at least in part, by inhibition of the increase in [Ca21]i
that is stimulated in untreated cells by pairs of anti-CD2
mAbs. Finally, the inability of treatment combinations af-
fecting [Ca2+]i-, cAMP-, and microfilament-mediated signal
transduction to reverse fully the immobilization of CD2 as-
sociated with cell activation suggests that other, [Ca2+]-
independent signal transduction pathways are also involved
in the regulation of CD2 mobility.
Several lines of evidence are consistent with the hypoth-
esis that mobilization of cytoplasmic Ca2+ mediates lateral
immobilization of CD2 at the cell surface. First, depletion of
intracellular Ca2+ partially prevents CD2 immobilization by
anti-CD2 mAb pairs. Second, loading cells with Db cAMP
and disrupting microfilaments with cytochalasin are two
other treatments that both inhibit cytoplasmic Ca2+ mobili-
zation and reverse CD2 immobilization to the same degree
as treatment with EGTA + ionomycin. Colchicine treatment
does not affect either [Ca2+]i or CD2 lateral mobility, and the
effects of neither Db cAMP nor cytochalasin are additive.
Third, cytoplasmic Ca2+ mobilization is temporally corre-
lated with CD2 immobilization.
We show here that Jurkat T cell activation correlates with
CD2 immobilization at the cell surface. Similar associations
between cell activation and decreased membrane receptor
mobility have been observed in neutrophils stimulated with
fMet-Leu-Phe (Johansson et al., 1993) and in the human T
cell line HPB-ALL stimulated with bivalent anti-CD3 mAb
(Hashemi et al., 1992). In several different systems, then, it
appears that either cell activation results in immobilization
of surface receptors or cell stimulation requires receptor mol-
ecules to be immobilized. In both neutrophils and HPB-ALL
we find that [Ca2+]i increases immediately before CD2 im-
mobilization. Increasing [Ca21]i could therefore serve to trig-
ger CD2 immobilization. Considering pairs of anti-CD2
mAbs as a model for ligand-induced cell activation, we pos-
tulate that ligand binding to CD2 causes activation-
associated release of intracellular Ca2 , which in part me-
diates CD2 immobilization.
We have recently found that activation of Jurkat T cells by
cross-linking the TCR/CD3 complex reduces CD2 fractional
mobility from 70 to 50%, and that the partial immobilization
of CD2 is completely reversed in cells depleted of [Ca2+]i
with EGTA + ionomycin (Liu and Golan, 1994a). In the
present study, we show that depletion of intracellular [Ca21]
partially reverses the CD2 immobilization induced by pairs
of anti-CD2 mAbs from an f value of 10% to 35%. The
difference (Af) between the fractional mobility of CD2 with
and without EGTA + ionomycin treatment is therefore 20-
25% in cells activated either by pairs of anti-CD2 mAbs or
by cross-linking the TCR/CD3 complex. Thus, the effects of
Ca21 mobilization on CD2 lateral mobility are similar for
cells activated through CD2 and TCR/CD3 pathways. We
have also found that calmodulin inhibition partially prevents
the CD2 immobilization induced by pairs of anti-CD2 mAbs
and completely prevents the CD2 immobilization stimulated
by cross-linking the TCR/CD3 complex (Liu and Golan,
1994b). These effects of calmodulin inhibition are consistent
with those of EGTA + ionomycin treatment, and with the
hypothesis that intermediate molecular events in the sig-
nal transduction pathway mediate Ca2+-induced CD2 im-
mobilization. Thus, activation-associated Ca2+ mobiliza-
tion appears to initiate an intracellular signaling pathway
that regulates CD2 lateral mobility in T cells, although
Ca2+-induced CD2 immobilization alone cannot account
for the degree of CD2 immobilization stimulated by pairs
of anti-CD2 mAbs.
Microfilaments are involved in a number of adhesive in-
teractions including co-aggregation ofW256 tumor cells and
platelets (Chopra et al., 1988) and self-aggregation of mouse
L cells transfected with liver cell adhesion molecules (Jaffe
et al., 1990). The cytoplasmic domain of the integrin CD54,
which together with CD2 mediates T cell adhesion, binds
directly to a-actinin and the actin-containing cytoskeleton
(Carpen et al., 1992). The observation that cytochalasin treat-
ment decreases sheep erythrocyte rosetting (SER) suggests
a possible role for microfilament integrity in T cell adhesion
mediated by CD2 (Freed et al., 1989; Ishijima et al., 1991).
We find here that cytochalasin treatment partially pre-
vents CD2 immobilization by activating pairs of anti-
CD2 mAbs. Because cytochalasin affects CD2 mobility
on mAb-treated but not resting cells, microfilament in-
tegrity appears to be important in activation-associated
CD2 immobilization but not in regulating CD2 mobility
in resting cells.
In the present study, cells were treated with 20 ,uM cyto-
chalasin, which is likely sufficient to disrupt cytosolic as well
cells, activation is associated with elevation of [Ca2+]j. Here
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1981). The inhibitory effects of cytochalasin on mAb-
induced [Ca2+]i mobilization and CD2 lateral immobilization
could therefore result from disruption of membrane-
associated and/or cytosolic microfilaments. Because actin
binding proteins (ABP) such as L-plastin and profilin play
important roles in coordinating and regulating actin poly-
merization and the structure of the actin network (Forscher,
1989; Pollard and Cooper, 1986; Kabsch and Vandekerck-
hove, 1992; Namba et al., 1992; Pacaud and Derancourt,
1993), ABP could also mediate interactions between [Ca21]i
and CD2. The abundant ABP L-plastin binds actin tightly
and cross-links (bundles) actin efficiently at low concentra-
tions of free calcium ions ([Ca21] < 150 nM); at higher cal-
cium concentrations (K, = 1600 nM), actin bundling is in-
hibited (Namba et al., 1992; Pacaud and Derancourt,
1993). ABP functions are regulated not only by Ca2' but
also by phosphatidylinositol-4,5-bisphosphate (PIP2)
(Forscher, 1989; Pollard and Cooper, 1986; Kabsch and
Vandekerckhove, 1992; Lassing and Lindberg, 1985;
Hartwig et al., 1989; Janmey and Stossel, 1989). Interactions
between profilin and PIP2 release actin monomers from
profilin/actin complexes (Lassing and Lindberg, 1985)
and protect PIP2 from hydrolysis by phospholipase C
(Goldschmidt-Clermont et al., 1990; 1991). ABP may there-
fore regulate polyphosphoinositide turnover as well as actin
remodeling (Forscher, 1989). Cytochalasin inhibits the po-
lymerization of actins by binding to the barbed ends of mi-
crofilaments and to actin dimers and monomers, with dis-
sociation constants ranging from 2.6 to 19.1 ,uM (Goddette
and Frieden, 1985; 1986). If cytochalasin binding to actin
prevents ABP such as profilin from binding to actin mono-
mers or to the barbed ends of actin filaments, cytochalasin
could cause ABP to be released from actin species and there-
fore to become available for binding to PIP2 and inhibiting
polyphosphoinositide turnover, even in the presence of ago-
nists that normally stimulate [Ca21]i mobilization. In turn,
impaired [Ca21]i mobilization could prevent the remodeling
of the actin network that is necessary for modulation of in-
teractions between microfilaments and cell surface CD2.
Phosphorylation of the ABP L-plastin has recently been
shown to be regulated by stimulation of Jurkat T cells
through CD2 (Henning et al., 1994), suggesting a second
mechanism by which cell activation could be linked to re-
modeling of the actin network. These models, although still
speculative, present attractive mechanisms by which intra-
cellular signals, the structure of the actin network, and CD2
lateral mobility could be mutually regulated.
We do not observe an effect of colchicine on CD2 lateral
mobility in either resting or activated cells. These results are
consistent with reports that colchicine does not affect SER
(Freed et al., 1989; Ishijima et al., 1991). We have previously
shown that CD2 physically interacts with a/P3 tubulin, and
that CD2-tubulin interactions are weakened by T cell acti-
vation induced by pairs of anti-CD2 mAbs (Offringa and
Bierer, 1993). The observation that colchicine treatment does
not affect the lateral mobility ofCD2 in resting cells suggests
may not be important in regulating CD2 mobility. It is not
surprising that colchicine does not reverse the lateral im-
mobilization of CD2 in activated cells, because T cell
activation has been shown previously to decrease CD2-
tubulin associations.
Intracellular cAMP increases upon binding of CD2 to its
natural ligand CD58 or to the mAb TS2/18 (Hahn et al., 1991;
Carrera et al., 1988). Further, this mediator regulates the
avidity of CD2:CD58 (Hahn et al., 1993) and CD54:CDlla/
CD18 (Dustin and Springer, 1989) interactions, as well as the
increase in T cell adhesion stimulated by TCR/CD3 cross-
linking (Dustin and Springer, 1989). Here we find that Db
cAMP inhibits the cytoplasmic Ca21 mobilization stimulated
by pairs of anti-CD2 mAbs. Together with the observations
that cAMP reduces diacylglycerol and inositol phosphate
generation stimulated by pairs of anti-CD2 mAbs (Bismuth
et al., 1988), these data suggest that cAMP inhibits inositol
trisphosphate-mediated intracellular Ca2' release. We also
find that Db cAMP treatment partially prevents CD2 im-
mobilization by pairs of anti-CD2 mAbs. The latter effect
may be secondary to cAMP-mediated inhibition of Ca2+ mo-
bilization. Elevation of intracellular cAMP causes actin de-
polymerization (Lamb et al., 1988; Hays and Lindberg, 1991;
Egan et al., 1991), which appears to be mediated by cAMP-
dependent protein kinase (Lamb et al., 1988). By inhibiting
actin polymerization and microfilament network remodel-
ing, increasing cAMP could modulate the immobilization of
CD2 induced by cell activation.
In T cell hybridomas, CD2 ligation by CD58, single anti-
CD2 mAbs, or pairs of anti-CD2 mAbs induces a transient
(10-15 min) increase in intracellular [cAMP] (Hahn et al.,
1991). Several considerations could explain the complete
(90%) lateral immobilization of CD2 by pairs of anti-CD2
mAbs under conditions that might be expected to increase
intracellular [cAMP]. First, the transient nature of the
[cAMP] response to pairs of anti-CD2 mAbs may be re-
sponsible for the delay observed here (Fig. 2) between mAb
treatment and both increased [Ca2+]i and decreased CD2 lat-
eral mobility. Second, the concentration of cAMP required
to prevent CD2 immobilization by pairs of anti-CD2 mAbs
(Table 2) may be greater than that induced by mAb treatment
(Hahn et al., 1991, 1993).
Surface receptor lateral mobility may play a role in
signal transduction. The fractional mobility of the vaso-
pressin V2-receptor increases linearly with vasopressin-
induced cAMP production in LLC-PK1 renal epithelial
cells, suggesting a role for V2-receptor mobility in
vasopressin-mediated adenylate cyclase activation (Jans
et al., 1991). Nerve growth factor receptors are preclus-
tered and laterally immobile on responsive cells but dif-
fusely distributed and laterally mobile on nonresponsive
cells, suggesting that receptor immobilization is required
for signal transduction (Venkatakrishnan et al., 1991).
Here we demonstrate that CD2 lateral mobility is regu-
lated by intracellular signals in Jurkat cells. Because
changes in receptor mobility markedly affect CD2-
that CD2-tubulin interactions at the plasma membrane
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1991), regulation of surface receptor lateral movement by
intracellular signals may serve as an important mecha-
nism by which cell activation is coupled to increased ad-
hesion strength.
Redistribution of adhesion molecules to contact areas
increases the strength of adhesion between Jurkat cells
and glass-supported planar membranes reconstituted with
laterally mobile CD58 (P.-Y. Chan et al., 1991; Ferguson
et al., 1991). Here we find that T cell activation through
CD2 induces rapid mobilization of cytoplasmic Ca2, fol-
lowed by lateral immobilization of cell surface CD2 mol-
ecules. During the 5-10 min interval between cytoplas-
mic Ca2 mobilization and CD2 immobilization,
anisotropic redistribution of CD2 molecules could occur.
By increasing intracellular cAMP, CD58 ligation of cell
surface CD2 at a contact site could prevent complete im-
mobilization of CD2 and thereby allow increased num-
bers of CD2 molecules to diffuse to the contact area.
Subsequent immobilization of CD2 could serve to main-
tain this adhesion molecule at high density at a contact
area, and thereby to increase cellular adhesion strength.
The importance of intracellular signaling in regulating
adhesion strength mediated by the CD2:CD58 receptor:
ligand pair has been demonstrated by SER assays. SER,
like treatment with pairs of anti-CD2 mAbs, causes an
increase in [Ca21]i in T cells (Ledbetter et al., 1988).
SER-associated intracellular Ca2 mobilization could
then induce CD2 immobilization. Inhibition of SER by
pretreatment of T cells with A23187 in the presence of
Ca>2 (Ishijima et al., 1991) could be due to CD2 immo-
bilization induced by increased [Ca2+]i, which would pre-
vent CD2 from diffusing to contact areas. In contrast,
inhibition of SER by pretreatment of T cells with cyto-
chalasin (Freed et al., 1989; Ishijima et al., 1991) could
be due to inhibition of CD2 immobilization at contact
sites by microfilament disruption. The timing of CD2 im-
mobilization in relationship to T cell activation may de-
termine whether adhesion is enhanced or inhibited.
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